Regeneus Ltd (ASX:RGS) Positive Clinical Trial Results for Progenza
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis, meeting the primary endpoint of safety and tolerability.